“We don’t know yet if this virus will be mutating away from the immune response,” the Oxford vaccine group’s director Andrew Pollard told reporters at a briefing, adding: “There is no evidence of that yet.”
Asked whether the vaccine – which showed at least 70% efficacy in interim data from phase III trials – would be likely to give longer-term protection, Pollard said: “We’ve got optimism about immune response lasting at least a year,” but that trials needed more time to be able to give any confirmation of durability.